Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage by respiratory pathogens among Greenlandic children

Background: In 2010, Greenland introduced the 13-valent pneumococcal conjugate vaccine (Prevnar 13®– PCV-13) in the childhood immunisation program. The authors aimed to evaluate the impact of PCV-13 on nasopharyngeal carriage of bacteria frequently associated with respiratory infections in children....

Full description

Bibliographic Details
Published in:International Journal of Circumpolar Health
Main Authors: Navne, Johan Emdal, Koch, Anders, Slotved, Hans-Christian, Andersson, Mikael, Melbye, Mads, Ladefoged, Karin, Børresen, Malene
Format: Text
Language:English
Published: Taylor & Francis 2017
Subjects:
Research Article
Greenland
greenlandic
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497538/
http://www.ncbi.nlm.nih.gov/pubmed/28467237
https://doi.org/10.1080/22423982.2017.1309504
Description
Summary:Background: In 2010, Greenland introduced the 13-valent pneumococcal conjugate vaccine (Prevnar 13®– PCV-13) in the childhood immunisation program. The authors aimed to evaluate the impact of PCV-13 on nasopharyngeal carriage of bacteria frequently associated with respiratory infections in children.

Similar Items